Proactive Investors
21 Sept 2026, 13:42 UTC · 1h ago
Verdict
Headline takes no side. We score TLSA +0.60 across two claims — strongly bullish.
+0.60strongly bullish
More positive than 70% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish · 2 new · 0 priced in
Tiziana Life Sciences expects to announce 12-week treatment topline data for its Phase 2a INFORM-MS trial in October.
Newsaid Monday
So whatThis catalyst creates a binary event for the lead candidate within 4-6 weeks, which will determine the viability of the na-SPMS pipeline.
More positive than 92% of claims this week
The company has completed all patient visits for the 48-patient Phase 2a trial of intranasal foralumab in non-active secondary progressive multiple sclerosis.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Newsaid Monday
So whatThe completion of the final visit allows for the database lock scheduled for this week, accelerating the timeline to data release.
More positive than 62% of claims this week
Which stocks this story touches
More positive than 70% of ticker scores this week
The company successfully completed the last patient visit in a Phase 2a clinical trial and reported positive outcomes from its Expanded Access Program.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Reuters
3d ago
+0.1%
Price flat so far
$0.9062 vs $0.9056 close before publication (Sep 18) · not market-adjusted
TLSA chart →
